Literature DB >> 26040662

Structural Characterisation of Non-Deamidated Acidic Variants of Erwinia chrysanthemi L-asparaginase Using Small-Angle X-ray Scattering and Ion-Mobility Mass Spectrometry.

David Gervais1, Darryl King2, Patrick Kanda2, Nicholas Foote2, Lucy Elliott2, Phillip Brown2, Natacha O Lee3, Konstantinos Thalassinos3, Claire Pizzey4, Robert Rambo4, Thomas C Minshull5, Mark J Dickman5, Stuart Smith2.   

Abstract

PURPOSE: Erwinia chrysanthemi L-asparaginase (ErA) is an enzyme commonly used in the treatment regimen for Acute Lymphoblastic Leukaemia (ALL). Biopharmaceutical products such as ErA must be monitored for modifications such as deamidation, typically using ion-exchange chromatography (IEX). Analysis of clinical-grade ErA using native IEX resolves a number of enzymatically-active, acidic variants that were poorly characterised.
METHODS: ErA IEX variants were isolated and fully characterised using capillary electrophoresis (cIEF), LC-MS and LC-MS/MS of proteolytic digests, and structural techniques including circular dichroism, small-angle X-ray scattering (SAXS) and ion-mobility mass spectrometry (IM-MS).
RESULTS: LC-MS, MS/MS and cIEF demonstrated that all ErA isolates consist mainly of enzyme lacking primary-sequence modifications (such as deamidation). Both SAXS and IM-MS revealed a different conformational state in the most prominent acidic IEX peak. However, SAXS data also suggested conformational differences between the main peak and major acidic variant were minor, based on comparisons with crystal structures.
CONCLUSIONS: IEX data for biopharmaceuticals such as ErA should be thoroughly characterised, as the most common modifications, such as deamidation, may be absent.

Entities:  

Keywords:  L-asparaginase; SAXS; deamidation; ion mobility; pH-induced conformational change

Mesh:

Substances:

Year:  2015        PMID: 26040662     DOI: 10.1007/s11095-015-1722-2

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  42 in total

1.  Validation of a pH gradient-based ion-exchange chromatography method for high-resolution monoclonal antibody charge variant separations.

Authors:  Jennifer C Rea; G Tony Moreno; Yun Lou; Dell Farnan
Journal:  J Pharm Biomed Anal       Date:  2010-09-29       Impact factor: 3.935

Review 2.  Applications of capillary electrophoresis in characterizing recombinant protein therapeutics.

Authors:  Shuai Sherry Zhao; David D Y Chen
Journal:  Electrophoresis       Date:  2013-11-22       Impact factor: 3.535

3.  Validation of a 30-year-old process for the manufacture of L-asparaginase from Erwinia chrysanthemi.

Authors:  David Gervais; Nigel Allison; Alan Jennings; Shane Jones; Trevor Marks
Journal:  Bioprocess Biosyst Eng       Date:  2012-08-21       Impact factor: 3.210

4.  Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats.

Authors:  Leslie A Khawli; Sirj Goswami; Ryan Hutchinson; Zephania W Kwong; Jihong Yang; Xiangdan Wang; Zhenling Yao; Alavattam Sreedhara; Tony Cano; Devin Tesar; Ihsan Nijem; David E Allison; Pin Yee Wong; Yung-Hsiang Kao; Cynthia Quan; Amita Joshi; Reed J Harris; Paul Motchnik
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

5.  Nucleotide sequence of the Erwinia chrysanthemi NCPPB 1066 L-asparaginase gene.

Authors:  N P Minton; H M Bullman; M D Scawen; T Atkinson; H J Gilbert
Journal:  Gene       Date:  1986       Impact factor: 3.688

6.  Structural analysis of prion proteins by means of drift cell and traveling wave ion mobility mass spectrometry.

Authors:  Gillian R Hilton; Konstantinos Thalassinos; Megan Grabenauer; Narinder Sanghera; Susan E Slade; Thomas Wyttenbach; Philip J Robinson; Teresa J T Pinheiro; Michael T Bowers; James H Scrivens
Journal:  J Am Soc Mass Spectrom       Date:  2010-01-28       Impact factor: 3.109

7.  A left-handed crossover involved in amidohydrolase catalysis. Crystal structure of Erwinia chrysanthemi L-asparaginase with bound L-aspartate.

Authors:  M Miller; J K Rao; A Wlodawer; M R Gribskov
Journal:  FEBS Lett       Date:  1993-08-16       Impact factor: 4.124

8.  Construction of expression systems for Escherichia coli asparaginase II and two-step purification of the recombinant enzyme from periplasmic extracts.

Authors:  E Harms; A Wehner; M P Jennings; K J Pugh; I R Beacham; K H Röhm
Journal:  Protein Expr Purif       Date:  1991 Apr-Jun       Impact factor: 1.650

9.  Mass spectrometry of intact V-type ATPases reveals bound lipids and the effects of nucleotide binding.

Authors:  Min Zhou; Nina Morgner; Nelson P Barrera; Argyris Politis; Shoshanna C Isaacson; Dijana Matak-Vinković; Takeshi Murata; Ricardo A Bernal; Daniela Stock; Carol V Robinson
Journal:  Science       Date:  2011-10-21       Impact factor: 47.728

10.  Collision cross sections for structural proteomics.

Authors:  Erik G Marklund; Matteo T Degiacomi; Carol V Robinson; Andrew J Baldwin; Justin L P Benesch
Journal:  Structure       Date:  2015-03-19       Impact factor: 5.006

View more
  2 in total

Review 1.  What makes a good new therapeutic L-asparaginase?

Authors:  Angela Beckett; David Gervais
Journal:  World J Microbiol Biotechnol       Date:  2019-09-24       Impact factor: 3.312

Review 2.  Quality Control and Downstream Processing of Therapeutic Enzymes.

Authors:  David Gervais
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.